linjc16/ctgov huggingface dataset:
Sarcopenia and Cirrhosis

Study Overview
=================
Brief Summary
-----------------
The study investigates the effect of aminoacid infusion on proteinturnover in muscle from cirrhosis subjects, compared to healthy controls. The hypothesis is that aminoacid infusion can attenuate the increase in proteindegradation that follows cirrhosis.

Conditions
-----------------
Cirrhosis

Intervention / Treatment
-----------------
* Dietary Supplement: Amino acid infusion
* Other: Bloodsamples, Biopsies.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male subjects Diagnosis of cirrhosis, Child-Pugh A, B, C. Exclusion Criteria: Acute illness within 3 weeks Ascites collections within 10 days Heart-, kidney, pulmonary disease. Cancer. Type 1 diabetes. Active alkoholdrinking

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Healthy controls<br>Amino acid infusion | Dietary Supplement: Amino acid infusion<br> <br> Other: Bloodsamples, Biopsies.<br> <br> |
| Active Comparator: Cirrhosis<br>Amino acid infusion | Dietary Supplement: Amino acid infusion<br> <br> Other: Bloodsamples, Biopsies.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Turnover of phenylalanine and tyrosine in skeletal muscle tissue during amino acid infusion. Inflammatory markers. Protein signaling cascade. | Using stable isotope tracer technique with infusion of phenylalanine and tyrosine tracer. Using ELISA technique. Using PCR and western blot technique. | 24 weeks |
Late Neutropenia in VLBW Preterm Babies

Study Overview
=================
Brief Summary
-----------------
There are rare reports regarding late neutropenua in very low birth weight preterm infants. The investigators wish to characterize it among our population, and assess its consequenses and the postnatal menagement of the infants.

Detailed Description
-----------------
There are rare reports regarding late neutropenua in very low birth weight preterm infants. The investigators wish to characterize it among our population, and assess its consequenses and the postnatal menagement of the infants.

Official Title
-----------------
Late Neutropenia in VLBW Preterm Babies - Characterization and Post Natal Menagement

Conditions
-----------------
Neutropenia

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm infant with birth weight up to 1500 gram Exclusion Criteria: Early neutroenia - neutrophil count < 1500 at the first week

Ages Eligible for Study
-----------------
Maximum Age: 30 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Late neutropenia<br>Neutrophil count < 1500 | Other: No intervention<br>* No intervention<br>|
| No late neutropenia<br>Neutrophil count > 1500 | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay | Number of days | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VLBW, Neutropenia
Prophylactic Pancreatic Stent for the Prevention of Post Operative Pancreatic Fistula

Study Overview
=================
Brief Summary
-----------------
Postoperative pancreatic fistula (POPF) remains one of the most harmful complications after pancreatic resection. Some studies have indicated that endoscopic pancreatic stenting was effective in the treatment of POPF. However, the results of prospective RCTs for the prophylactic effect of pancreatic stent insertion against POPF were controversial. This single center prospective randomized trial was designed to compare the outcome after segmental pancreatectomy with prophylactic drainage stent versus no stent.

Official Title
-----------------
Prophylactic Pancreatic Stent for the Prevention of Post Operative Pancreatic Fistula Before Segmental Pancreatectomy

Conditions
-----------------
Pancreatic Fistula

Intervention / Treatment
-----------------
* Device: Prophylactic pancreatic stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients scheduled for elective segmental pancreatectomy Exclusion Criteria: Subjects for whom ERCP procedures are contraindicated If female, pregnant based on a positive hCG serum or an in vitro diagnostic test result or breast-feeding Age less than 18 year Emergency surgery Previous pancreatic surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stent<br>Prophylactic pancreatic stent before segmental pancreatic surgery | Device: Prophylactic pancreatic stent<br>* Prophylactic pancreatic stent before segmental pancreatic surgery<br>|
| No Intervention: No stent<br>No prophylactic stent before surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pancreatic fistula | Grade B and C | from postoperative day 3 to 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of pancreatic fistula | Grade B POPF requires changes in clinical management, such as persistent drainage, partial or total parenteral nutrition, antibiotics, enteral nutrition, somatostatin analogs, and/or minimal invasive drainage. Grade C POPF requires major changes in management, such as admission to an intensive care unit, reoperation, and/or an extended hospital stay. | from postoperative day 3 to 30 | 
| Length of stay | Length of hospital stay | from postoperative day 1 to discharge |
Survey of People With Diabetes, Caregivers of People With Diabetes Parents of Children and Young People With Diabetes

Study Overview
=================
Brief Summary
-----------------
A survey of people with diabetes and caregivers of people with diabetes and parents of children and young people with diabetes in Denmark in order to assess perceived diabetes related health and wellbeing and perceived access to and gaps in medical care, support and other financial and support services.

Detailed Description
-----------------
A questionnaire survey was designed for online completion by people with diabetes and caregivers of people with diabetes and parents of children and young people with diabetes in Denmark in order to assess their perceived diabetes related health and wellbeing and perceived access to and gaps in medical care, support and other financial and support services. The aim is for the survey to provide a cross-sectional assessment of present access to health, wellbeing and care for people with diabetes and caregivers in Denmark and to establish a survey tool suitable for ongoing long-term monitoring of well-being, care and support to people with diabetes and caregivers in Denmark.

Official Title
-----------------
Danish Diabetes Barometer Survey 2019

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 Exclusion Criteria: Not able to complete online questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Survey population<br>Adults with type 1 and type 2 diabetes and caregivers of people with diabetes including parents of children and young people with diabetes. | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diabetes membership survey of health, access to care, support and services | Study-specific Likert-scale single item variables for perceived health, access to diabetes care, support and services (1-5) | The survey was administered from April 11 to 29th 2019 |
Effects of Electrical Stimulation on Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out whether electrical stimulation can reduce knee pain and increase function in people with osteoarthritis of the knee.

Official Title
-----------------
Effects of Electrical Stimulation on Osteoarthritis of the Knee

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Device: InterX 5000


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50 years of age or older Diagnosis of primary osteoarthritis of the knee (as defined by American College of Rheumatology criteria) Knee pain of at least six months duration Moderate or greater knee pain (defined as a score of 3 or greater on an 11 point numeric pain rating scale) for most days in the last month Willing to abide by protocol and treatment schedule. Exclusion Criteria: Implants, such as pacemaker, TENS, or insulin pump, incompatible with electrical stimulation Uncontrolled concomitant disease affecting the knee, such as: rheumatoid arthritis, systemic lupus erythema, psoriatic arthritis Pregnant or breast-feeding Intra-articular corticosteroid or hyaluronic acid injection into the knee within 3 months preceding study Arthroscopy of the knee within the past year Significant injury to the knee within the past 6 months Use of assistive devices other than a cane or knee brace Disease of spine or other lower extremity joints of sufficient degree to affect assessment of the knee

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Device: InterX 5000<br>* 20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.<br>* Other names: Noninvasive Interactive Neurostimulation;|
| Placebo Comparator: 2<br> | Device: InterX 5000<br>* 20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.<br>* Other names: Noninvasive Interactive Neurostimulation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Pain |  | Baseline, Week 4, Week 8, and Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee function |  | Baseline, Week 4, Week 8, and Week 12 | 
| Knee stiffness |  | Baseline, Week 4, Week 8, and Week 12 | 
| Patient global assessment |  | Baseline, Week 4, Week 8, and Week 12 | 
| Health-related quality of life |  | Baseline, Week 4, Week 8, and Week 12 |
Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine mean or median of fractional exhaled nitric oxide (FeNO) in Thai atopic asthmatic children that divided into subgroups due to asthma exacerbation according to the global initiative for asthma guideline.

Detailed Description
-----------------
From many previous studies, fractional exhaled nitric oxide (FeNO) has many benefits such as non-invasive, easily to perform, less time consume, has direct association with severity of inflammation of bronchial trees and sputum eosinophils, has benefit for diagnosis and monitoring the treatment in asthmatic patients. In Thailand, this field of study is less extend, especially in children population. The investigators hypothesized that patients with asthma exacerbation may have high level of fractional exhaled nitric oxide (FeNO) than non exacerbation group. It is therefore desirable to examine the association between fractional exhaled nitric oxide (FeNO) and asthma exacerbation among atopic asthmatic Thai children and will be the main objective of this research.

Official Title
-----------------
Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation

Conditions
-----------------
Bronchial Asthma

Intervention / Treatment
-----------------
* Other: FeNO measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of atopic bronchial asthma follow up in clinic of allergy and clinical immunology, Siriraj hospital Exclusion Criteria: smoker or past history of smoking chronic disease eg. HIV infection, pulmonary hypertension, systemic lupus erythematosus, liver cirrhosis, gastroesophageal reflux, COPD, bronchiectasis drink ethanol within 48 hours before enrollment history of upper or lower respiratory tract infection within 6 weeks before enrollment drink caffeine within day before enrollment during pregnancy history of systemic steroid use within 8 weeks before enrollment

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of asthma exacerbation in the studied cases with different FeNO levels | Occurrence of asthma exacerbation in 1 year after the study | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bronchial asthma, fractional exhaled nitric oxide (FeNO), asthma exacerbation
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Study Overview
=================
Brief Summary
-----------------
This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Detailed Description
-----------------
People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

Official Title
-----------------
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Conditions
-----------------
Retinal Vein Occlusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who have been enrolled in the following three trials will be included in the study: A) A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions., B) Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN)  C) RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE) Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treated with Ranibizumab in previous trial<br>Treated with Ranibizumab in previous trial | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in BCVA at 5 and 10 years. | Mean change from baseline in BCVA at 5 and 10 years. | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in foveal thickness at 5 and 10 years | Mean change from baseline in foveal thickness at 5 and 10 years | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinal Vein Occlusion
Androgens for Poor Responders in In Vitro Fertilization

Study Overview
=================
Brief Summary
-----------------
it has been shown that androgens in non human primates may favour follicular growth in the ovaries when animals are treated with gonadotropins which are the hormones used in patients receiving treatment with in vitro fertilization. Therefore, this study investigates the potential usefulness of testosterone treatment preceding gonadotropin administration in in vitro fertilization patients having a previous poor response to gonadotropins alone.

Official Title
-----------------
Transdermal Testosterone to Improve Ovarian Response to Gonadotropins in Poor Responder IVF Patients With Normal Basal Concentrations of FSH

Conditions
-----------------
Ovarian Response

Intervention / Treatment
-----------------
* Drug: Transdermal testosterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving the second IVF treatment attempt having the first treatment cycle cancelled because of poor ovarian response to gonadotropins Exclusion Criteria: Previous ovarian surgery Clinical or laboratory profile suggesting premature ovarian failure

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles | Drug: Transdermal testosterone<br> <br> |
| No Intervention: 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, Poor, Response, Ovarian, Stimulation, Patients
Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate whether RIPC protects the heart against ischemia reperfusion injury on the concentrically hypertrophied myocardium

Conditions
-----------------
Patients With Elective Aortic Valve Replacement

Intervention / Treatment
-----------------
* Procedure: Remote ischemic preconditioning at left upper arm
* Procedure: Control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥20 years with severe degenerative AS presenting concentric remodeling of the LV, who were scheduled for AVR Exclusion Criteria: diabetes mellitus, coronary stenosis ≥70%, renal failure (serum creatinine > 2.0 mg/dL), upper arm peripheral vascular disease, LV ejection fraction <50%

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RIPC group<br> | Procedure: Remote ischemic preconditioning at left upper arm<br>* Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) & 5 min reperfusion (deflation)<br>|
| Placebo Comparator: Control group<br> | Procedure: Control group<br>* keeping the cuff deflated<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum levels of CK-MB and Tn-T |  | baseline | 
| Serum levels of CK-MB and Tn-T |  | 12-hour after surgery | 
| Serum levels of CK-MB and Tn-T |  | 24-hour after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myocardial activation of protective signaling pathway |  | Before commencement of CPB | 
| Myocardial activation of protective signaling pathway |  | After taking off CPB | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Remote ischemic preconditioning, cardiac surgery, left ventricular hypertrophy, reperfusion injury salvage kinase